We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Sangamo Therapeutics Inc (SGMO) Com Stk USD0.01

Sell:$2.41 Buy:$2.50 Change: $0.11 (4.60%)
Market closed |  Prices as at close on 24 December 2024 | Switch to live prices |
Sell:$2.41
Buy:$2.50
Change: $0.11 (4.60%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 24 December 2024 | Switch to live prices |
Sell:$2.41
Buy:$2.50
Change: $0.11 (4.60%)
Market closed |  Prices as at close on 24 December 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Sangamo Therapeutics, Inc. is a genomic medicines company that is developing medicines for neurological diseases. The Company's neurology preclinical development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases, and development of novel engineered adeno-associated virus (AAV) capsids to deliver its therapies to the intended neurological targets. The Company's zinc finger epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid discovery platform is expanding delivery beyond intrathecal delivery capsids, including in the central nervous system. Its clinical-stage product candidates are Isaralgagene civaparvovec, also known as ST-920, its wholly-owned gene therapy product candidate for the treatment of Fabry disease, and TX200, its wholly-owned CAR-Treg cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation.

Contact details

Address:
501 Canal Blvd.
RICHMOND
94084
United States
Telephone:
+1 (510) 9706000
Website:
https://www.sangamo.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
SGMO
ISIN:
US8006771062
Market cap:
$521.62 million
Shares in issue:
208.65 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Alexander Macrae
    President, Chief Executive Officer, Director
  • Prathyusha Duraibabu
    Chief Financial Officer, Senior Vice President
  • Scott Willoughby
    Senior Vice President, General Counsel, Corporate Secretary
  • Nathalie Dubois- Stringfellow
    Senior Vice President, Chief Development Officer
  • Amy Pooler
    Vice President, Head of Research

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.